Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders

Current Protocols in Pharmacology

Volumn , Issue SUPPL. 43, 2008, Pages

  Gavrilescu, L Cristina ^a   Van Etten, Richard A ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

BCR ABL; Chronic myeloid leukemia; JAK2; Lymphoma; Mouse model; Polycythemia vera

Indexed keywords

BCR ABL PROTEIN; PROTEIN TYROSINE KINASE; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; B CELL LEUKEMIA; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL STRAIN HEK293; CULTURE MEDIUM; DRUG CHOICE; EXPERIMENTAL MODEL; FEMALE; FLOW CYTOMETRY; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; METHODOLOGY; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOUTHERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CULTURE MEDIA; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FLUOROURACIL; GENES, ABL; HEK293 CELLS; HUMANS; LEUKEMIA, B-CELL; MALE; MICE; MICE, INBRED BALB C; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM TRANSPLANTATION; PROTEIN-TYROSINE KINASES; RETROVIRIDAE; SPECIMEN HANDLING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 63849234790     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph1410s43     Document Type: Review

References (74)

1. Barnes, D.J., Schultheis, B., Adedeji, S., and Melo, J.V. 2005. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24:6432-6440.
2. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N., Green, A.R., and Cancer Genome Project 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061.
3. Bhattacharya, D., Rossi, D.J., Bryder, D., and Weissman, I.L. 2006. Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning. J. Exp. Med. 203:73-85.
4. Brown, T. 1999. Southern blotting. Curr. Protoc. Mol. Biol. 68:2.9.1-2.9.20.
5. Cherry, S.R., Biniszkiewicz, D., van Parijs, L., Baltimore, D., and Jaenisch, R. 2000. Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol. Cell. Biol. 20:7419-7426.
6. Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Lagare, R.D., Cottes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., Cross, N.C., Tefferi, A., Malone, J., Alam, R., Schrier, S.L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S.E., Stone, R., Gilliland, D.G. 2003. A tyrosine kinase created by fusion of the PDGFA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:1201-1214.
7. bcr/abl gene of the Philadelphia chromosome. Science 247:824-830.
8. Dameshek, W. 1951. Some speculations on the myeloproliferative disorders. Blood 6:372-375.
9. Gallagher, S.R. and Desjardins, P.R. 2006. Quantitation of DNA and RNA with absorption and fluorescence spectroscopy. Curr. Protoc. Mol. Biol. 76:A.3D.1-A.3D.21.
10. Demiroglu, A., Steer, E.J., Heath, C., Taylor, K., Bentley, M., Allen, S.L., Koduru, P., Brody, J.P., Hawson, G., Rodwell, R., Doody, M.L., Carnicero, F., Reiter, A., Goldman, J.M., Melo, J.V., and Cross, N.C. 2001. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 98:3778-3783.
11. Donovan, J. and Brown, P. 2006a. Parenteral injections. Curr. Protoc. Immunol. 73:1.6.1-1.6.10.
12. Donovan, J. and Brown, P. 2006b. Euthanasia. Curr. Protoc. Immunol. 73:1.8.1-1.8.4.
13. Donovan, J. and Brown, P. 2006c. Blood collection. Curr. Protoc. Immunol. 73:1.7.1-1.7.9.
14. DuBridge, R.B., Tang, P., Hsia, H.C., Leong, P.M., Miller, J.H., and Calos, M.P. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
15. Fialkow, P.J., Jacobson, R.J., and Papayannopoulou, T. 1977. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 63:125-130.
16. Finer, M.H., Dull, T.J., Qin, L., Farson, D., and Roberts, M. 1994. kat: A high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 83:43-50.
17. Fioretos, T., Panagopoulos, I., Lassen, C., Swedin, A., Billstrom, R., Isaksson, M., Strombeck, B., Olofsson, T., Mitelman, F., and Johansson, B. 2001. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: The first fusion gene involving BCR but not ABL. Gene. Chromosome Canc. 32:302-310.
18. Fletcher, F.A., Moore, K.A., Ashkenazi, M., DeVries, P., Overbeek, P.A., Williams, D.E., and Belmont, J.W. 1991. Leukemia inhibitory factor improves survival of retroviral vector-infected hematopoietic stem cells in vitro, allowing efficient long-term expression of vector-encoded human adenosine deaminase in vivo. J. Exp. Med. 174:837-845.
19. Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J.H., Ashman, L.K., and Kanayama, Y. 1993. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736-1744.
20. Golub, T.R., Barker, G.F., Lovett, M., and Gilliland, D.G. 1994. Fusion of the PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-316.
21. Griffin, J.H., Leung, J., Bruner, R.J., Caligiuri, M.A., and Briesewitz, R. 2003. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. U.S.A. 100:7830-7835.
22. Hanenberg, H., Xiao, X.L., Dilloo, D., Hashino, K., Kato, I., and Williams, D.A. 1996. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2:876-882.
23. Hardy, R.R., Carmack, C.E., Shinton, S.A., Kemp, J.D., and Hayakawa, K. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173:1213-1225.
24. Heisterkamp, N., Jenster, G., Kioussis, D., Pattengale, P.K., and Groffen, J. 1991. Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Res. 1:45-53.
25. Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R.A., and Li, S. 2004. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36:453-461.
26. Hu, Y., Swerdlow, S., Duffy, T.M., Weinmann, R., Lee, F.Y., and Li, S. 2006. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. U.S.A. 103:16870-16875.
27. Huettner, C.S., Zhang, P., Van Etten, R.A., and Tenen, D.G. 2000. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24:57-60.
28. Inhorn, R.C., Aster, J.C., Roach, S.A., Slapak, C.A., Soiffer, R. Tantravahi, R., and Stone, R.M. 1995. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): Description of a distinctive clinicopathological entity. Blood 85:1881-1887.
29. Jaiswal, S., Traver, D., Miyamoto, T., Akashi, K., Lagasse, E., and Weissman, I.L. 2003. Expression of BCR/ABL and BCL2 in myeloid progenitors leads to myeloid leukemias. Proc. Natl. Acad. Sci. U.S.A. 100:10002-10007.
30. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N., and Vainchenker, W. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148.
31. Jiang, X., Stuible, M., Chalandon, Y., Li, A., Chan, W.Y., Eisterer, W., Krystal, G., Eaves, A., and Eaves, C. 2003. Evidence for a positive role of SHIP in BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 102:2976-2984.
32. Jones, A.V. and Cross, N.C. 2004. Oncogenic derivatives of platelet-derived growth factor receptors. Cell. Mol. Life Sci. 61:2912-2923.
33. Kotani, H., Newton, P.B. 3rd, Zhang, S., Chiang, Y.L., Otto, E., Weaver, L., Blaese, R.M., Anderson, W.F., and McGarrity, G.J. 1994. Improved-methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5:19-28.
34. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M., and Skoda, R.C. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:1779-1790.
35. Krause, D.S. and Van Etten, R.A. 2004. Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model. Blood 104:4236-4244.
36. Krause, D.S., and Van Etten, R.A. 2005. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353:172-187.
37. Lacout, C., Pisani, D.F., Tulliez, M., Gachelin, F.M., Vainchenker, W., and Villeval, J.L. 2006. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108:1652-1660.
38. Lee, J.C., Hapel, A.J., and Ihle, J.N. 1982. Constitutive production of a unique lymphokine (IL 3) by theWEHI-3 cell line. J. Immunol. 128:2393-2398.
39. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Fröhling, S., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J., and Gilliland, D.G. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397.
40. Li, S., Ilaria, R.L., Million, R.P., Daley, G.Q., and Van Etten, R.A. 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189:1399-1412.
41. Li, S., Gillessen, S., Tomasson, M.H., Dranoff, G., Gilliland, D.G., and Van Etten, R.A. (2001). Interleukin-3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 97:1442-1450.
42. Macdonald, D., Aguiar, R.C., Mason, P.J., Goldman, J.M., and Cross, N.C. 1995. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: A review. Leukemia 9:1628-1630.
43. Macdonald, D., Reiter, A., and Cross, N.C.P. 2002. The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1. Acta. Haematol. 107:101-107.
44. McLaughlin, J., Chianese, E., and Witte,O.N. 1987. In vitro transformation of immature hematopoietic cells by the P210 bcr/abl oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. U.S.A. 84:6558-6562.
45. McLaughlin, J., Chianese, E., and Witte, O.N. 1989. Alternative forms of the bcr-abl oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol. Cell Biol. 9:1866-1874.
46. Miles, C., Sanchez, M.J., Sinclair, A., and Dzierzak, E. 1997. Expression of the Ly-6E.1 (Sca-1) transgene in adult hematopoietic stem cells and the developing mouse embryo. Development 124:537-547.
47. Million, R.P., Aster, J., Gilliland, D.G., and Van Etten, R.A. 2002. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 99:4568-4577.
48. Naviaux, R.K., Costanzi, E., Haas, M., and Verma, I.M. 1996. The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70:5701-5705.
49. Neering, S.J., Bushnell, T., Sozer, S., Ashton, J., Rossi, R.M., Wang, P.Y., Bell, D.R., Heinrich, D., Bottaro, A., and Jordan, C.T. 2007. Leukemia stem cells in a genetically defined murine model of blast crisis CML. Blood 110:2578-2585.
50. Ory, D.S., Neugeboren, B.A., and Mulligan, R.C. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U.S.A. 93:11400-11406.
51. Parganas, E., Wang, D., Stravopodis, D., Topham, D.J., Marine, J.C., Teglund, S., Vanin, E.F., Bodner, S., Colamonici, O.R., van Deursen, J.M., Grosveld, G., and Ihle, J.N. 1998. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385-395.
52. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U.S.A. 90:8392-8396.
53. Pear, W.S., Miller, J.P., Xu, L., Pui, J.C., Soffer, B., Quackenbush, R.C., Pendergast, A.M., Bronson, R., Aster, J.C., Scott, M.L., and Baltimore, D. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease inmice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-3792.
54. Phelan, M.C. 2006. Techniques for mammalian cell tissue culture. Curr. Protoc. Mol. Biol. 74:A.3F.1-A.3F.18.
55. Randall, T.D. and Weissman, I.L. 1997. Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood 89:3596-3606.
56. Rosenberg, N. and Baltimore, D. 1976. A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J. Exp. Med. 143:1453-1463.
57. Roumiantsev, S., de Aos, I., Varticovski, L., Ilaria, R.L., and Van Etten, R.A. 2001. The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97:4-13.
58. Roumiantsev, S., Krause, D.S., Neumann, C.A., Dimitri, C.A., Asiedu, F., Cross, N.C., and Van Etten, R.A. 2004. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 5:287-298.
59. Smith, K.M., Yacobi, R., and Van Etten, R.A. 2003. Autoinhibition of Bcr-Abl through its SH3 domain. Mol. Cell. 12:27-37.
60. Southern, E.M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517.
61. Stocking, C., Kollek, R., Bergholz, U., and Ostertag, W. 1985. Long terminal repeat sequences impart hematopoietic transformation properties to the myeloproliferative sarcoma virus. Proc. Natl. Acad. Sci. U.S.A. 82:5746-5750.
62. Swift, S., Lorens, J., Achacoso, P., and Nolan, G.P. 1999. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr. Protoc. Immunol. 10.17.14-10.17.29.
63. Van Etten, R.A. 2001a. Models of chronic myeloid leukemia. Curr. Oncol. Rep. 3:228-237.
64. Van Etten, R.A. 2001b. Retroviral transduction models of Ph+ leukemia: Advantages and limitations for modeling human hematological malignancies in mice. Blood Cells Mol. Dis. 27:201-205.
65. + leukemia in mice. Oncogene 21:8643-8651.
66. Van Etten, R.A. and Shannon, K.M. 2004. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6:547-552.
67. Vardiman, J.W., Harris, N.L., and Brunning, R.D. 2002. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302.
68. Voytas, D. 2000. Agarose gel electrophoresis. Curr. Protoc. Mol. Biol. 51:2.5A.1-2.5A.9.
69. Voytas, D. and Ke, N. 1999. Detection and quantitation of radiolabeled proteins and DNA in gels and blots. Curr. Protoc. Mol. Biol. 48:A.3A.1-A.3A.10.
70. Wernig, G., Mercher, T., Okabe, R., Levine, R.L., Lee, B.H., and Gilliland, D.G. 2006. Expression of Jak2V617F causes a polycythemia veralike disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107:4274-4281.
71. Wolff, N.C. and Ilaria, R.L.J. 2001. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98:2808-2816.
72. Xiao, S., Nalabolu, S.R., Aster, J.C., Ma, J., Abruzzo, L., Jaffe, E.S., Stone, R., Weissman, S.M., Hudson, T.J., and Fletcher, J.A. 1998. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/ lymphoma syndrome. Nat. Genet. 18:84-87.
73. Zaleskas, V.M., Krause, D.S., Lazarides, K., Patel, N., Hu, Y., Li, S., and Van Etten, R.A. 2006. Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F. PLoS ONE 1:e18.
74. Zhang, X. and Ren, R. 1998. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia. Blood 92:3829-3840.